126 related articles for article (PubMed ID: 33223550)
1. Feasibility and outcomes of a hepatitis C screening programme in community pharmacies.
Gauld N; Perry J; Jackson C; Gane E
N Z Med J; 2020 Nov; 133(1525):74-83. PubMed ID: 33223550
[TBL] [Abstract][Full Text] [Related]
2. Pharmacist-initiated hepatitis C virus screening in a community pharmacy to increase awareness and link to care at the medical center.
Isho NY; Kachlic MD; Marcelo JC; Martin MT
J Am Pharm Assoc (2003); 2017; 57(3S):S259-S264. PubMed ID: 28506379
[TBL] [Abstract][Full Text] [Related]
3. Patient awareness, willingness, and barriers to point-of-care hepatitis C screening in community pharmacy.
Brewer A; Hanna C; Eckmann L; Schadler A; Divine H
J Am Pharm Assoc (2003); 2018; 58(4S):S69-S72.e1. PubMed ID: 30006188
[TBL] [Abstract][Full Text] [Related]
4. Pharmacists performing hepatitis C antibody point-of-care screening in a community pharmacy: A pilot project.
Dong BJ; Lopez M; Cocohoba J
J Am Pharm Assoc (2003); 2017; 57(4):510-515.e2. PubMed ID: 28602784
[TBL] [Abstract][Full Text] [Related]
5. Innovating the Model for Student Pharmacists to Increase Access to Hepatitis C Testing (Project IMPACT).
Januszka J; Notarianni V; Devenny E; Harris E
J Am Pharm Assoc (2003); 2023; 63(4):1217-1221. PubMed ID: 37037394
[TBL] [Abstract][Full Text] [Related]
6. Pharmacist Comfort and Awareness of HIV and HCV Point-of-Care Testing in Community Settings.
Min AC; Andres JL; Grover AB; Megherea O
Health Promot Pract; 2020 Sep; 21(5):831-837. PubMed ID: 31257939
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus screening in community pharmacies: results on feasibility from a Swiss pilot.
Stämpfli D; Imfeld-Isenegger TL; Hersberger KE; Messerli M
BMC Infect Dis; 2023 Jun; 23(1):384. PubMed ID: 37286975
[TBL] [Abstract][Full Text] [Related]
8. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
[TBL] [Abstract][Full Text] [Related]
9. DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy.
Radley A; Tait J; Dillon JF
Int J Drug Policy; 2017 Sep; 47():126-136. PubMed ID: 28647161
[TBL] [Abstract][Full Text] [Related]
10. Time and motion study of hepatitis C virus point-of-care testing in community pharmacies.
Beuschel T; Gootee E; Jordan M; Sikkenga T; Klepser DG; Holmquist H; de Voest A; Klepser ME
J Am Pharm Assoc (2003); 2023; 63(1):435-439. PubMed ID: 36463010
[TBL] [Abstract][Full Text] [Related]
11. Expanding access to HIV testing through Canadian community pharmacies: findings from the APPROACH study.
Kelly DV; Kielly J; Hughes C; Gahagan J; Asghari S; Hancock S; Burt K; Smyczek P; Charlton C; Nguyen H
BMC Public Health; 2020 May; 20(1):639. PubMed ID: 32380978
[TBL] [Abstract][Full Text] [Related]
12. Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study.
Williams B; Howell J; Doyle J; Thompson AJ; Draper B; Layton C; Latham N; Bramwell F; Membrey D; Mcpherson M; Roney J; Stoové M; Hellard ME; Pedrana A
Int J Drug Policy; 2019 Oct; 72():91-98. PubMed ID: 31129023
[TBL] [Abstract][Full Text] [Related]
13. Primary Care Perspectives on Hepatitis C Virus Screening, Diagnosis and Linking Patients to Appropriate Care.
Lebovics E; Torres R; Porter LK
Am J Med; 2017 Feb; 130(2):S1-S2. PubMed ID: 28087291
[TBL] [Abstract][Full Text] [Related]
14. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
[TBL] [Abstract][Full Text] [Related]
15. Implementation and Evaluation of a Collaborative, Pharmacy-Based Hepatitis C and HIV Screening Program.
Klepser DG; Klepser ME; Peters PJ; Hoover KW; Weidle PJ
Prev Chronic Dis; 2022 Dec; 19():E83. PubMed ID: 36480802
[TBL] [Abstract][Full Text] [Related]
16. Liver health events: an indigenous community-led model to enhance HCV screening and linkage to care.
Pandey M; Konrad S; Reed N; Ahenakew V; Isbister P; Isbister T; Gallagher L; Campbell T; Skinner S
Health Promot Int; 2022 Feb; 37(1):. PubMed ID: 34125199
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of hepatitis C virus testing and linkage in community supervision offices: Great potential but persistent challenges.
Jacka BP; Bazerman LB; Dickerson C; Moody M; Martin J; Patry E; Cady T; Compere H; Boudreau M; Beckwith CG
Int J Drug Policy; 2022 May; 103():103668. PubMed ID: 35367903
[TBL] [Abstract][Full Text] [Related]
18. Improving Screening Methods for Hepatitis C Among People Who Inject Drugs: Findings from the HepTLC Initiative, 2012-2014.
Blackburn NA; Patel RC; Zibbell JE
Public Health Rep; 2016; 131 Suppl 2(Suppl 2):91-7. PubMed ID: 27168667
[TBL] [Abstract][Full Text] [Related]
19. Crowdsourcing to promote hepatitis C testing and linkage-to-care in China: a randomized controlled trial protocol.
Wong WCW; Yang NS; Li J; Li H; Wan EYF; Fitzpatrick T; Xiong Y; Seto WK; Chan P; Liu R; Tang W; Tucker JD
BMC Public Health; 2020 Jul; 20(1):1048. PubMed ID: 32615951
[TBL] [Abstract][Full Text] [Related]
20. Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia.
Saludes V; Antuori A; Folch C; González N; Ibáñez N; Majó X; Colom J; Matas L; Casabona J; Martró E;
Int J Drug Policy; 2019 Dec; 74():236-245. PubMed ID: 31706159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
